RxDoctor Payments DataLook up a doctor →

William Hollins, MD

Sleep Medicine · Columbia, SCNPI 1164422820

Payments from drug & device makers

$322,847in general payments, 2019–2025

Across 695 payments — averaging $464.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$161K
  • Amarin Pharma, Inc.$35K
  • Amgen$34K
  • Lilly USA, LLC$31K
  • Boehringer Ingelheim$21K
  • Esperion Therapeutics, Inc.$14K
  • plus $27K from 38 others

What the payments were for

  • Consulting fees$6,1504%
  • Speaking & faculty fees$114,77178%
  • Travel & lodging$14,22510%
  • Food & beverage$12,1458%
  • Education$1790%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$322,847 in reported general payments places this provider in the 95th percentile of 25 sleep medicine providers in South Carolina.

See all sleep medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$396,326
Medicare patients
2,452
Services billed
6,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban440$393,472
Repatha SureclickEvolocumab291$246,226
XareltoRivaroxaban242$237,706
EntrestoSacubitril/Valsartan177$188,711
JardianceEmpagliflozin167$181,245
MounjaroTirzepatide67$101,935
OzempicSemaglutide45$59,375
TrulicityDulaglutide34$46,828
VascepaIcosapent Ethyl62$38,044
GlyxambiEmpagliflozin/Linagliptin32$34,949
BrilintaTicagrelor38$33,991
JanuviaSitagliptin Phosphate38$33,427
NexlizetBempedoic Acid/Ezetimibe43$31,420
FarxigaDapagliflozin Propanediol38$30,553
Icosapent Ethyl95$25,165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$412$393,472440 claims
Johnson & JohnsonXarelto$7,874$237,706242 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta$21,142$235,365225 claims
NovartisEntresto$160,667$188,711177 claims
Lilly USA, LLCMounjaro, Trulicity$31,145$148,764101 claims
Novo NordiskOzempic, Wegovy$433$73,35456 claims
AstraZenecaBrilinta, Farxiga$273$64,54476 claims
MerckJanuvia, Janumet Xr$446$45,99650 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$14,153$43,60363 claims
BayerKerendia$231$8,19811 claims
Kowa Pharmaceuticals America, Inc.Bystolic$63$2,86111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 25 sleep medicine providers in South Carolina.

Other sleep medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →